靶向治疗的崛起标志着肺癌治疗迈入了一个全新的精准医疗时代。近年来，随着精准医疗理念的深入实践，肺癌靶向药物的研究与应用范围已从常见的突变靶点逐步扩展至更为少见的突变靶点。在非小细胞肺癌（NSCLC）领域，针对罕见靶点从检测到治疗取得了不少令人瞩目的进 ...

BRAF V600E mutations are common in different tumor types (more frequently in melanomas, colon and thyroid carcinomas). BRAF Alterations in Brain Tumors: Different Diagnostic Relevance of BRAF ...

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.